Research Synthesis: Oral Microbiome Periodontal Aging

Research Synthesis: Oral Microbiome Periodontal Aging

Abstract

Evidence-honesty note: 13/13 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes oral microbiome periodontal aging as an aging-related intervention across 13 included source papers and 392 high-confidence extracted claims.

The evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 13 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 37 cross-study disagreements across the evidence base.

No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence, immune and inflammation, safety and comorbidity outcome classes, and negative signals cluster in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that oral microbiome periodontal aging should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

Methods

Review type and protocol

This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-oral_microbiome_periodontal_aging-v06-DAILY-2026-06-05T12-02-09Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-05.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• periodontitis AND aging AND inflammation
• oral microbiome AND cardiovascular risk AND cohort
• periodontal disease AND dementia AND meta-analysis
• periodontal therapy AND inflammation AND randomized
• oral dysbiosis AND frailty

Eligibility criteria

• Sources whose primary content addresses oral microbiome periodontal aging.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 313 records in the receipt-candidate union, 73 were classified as source candidates and 13 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	313
Classified source candidates	73
No extractable claims	108
None-only claim binding	19
Mixed partial-or-none claim-binding candidates	76
Partial-only claim-binding candidates	33
Strict high-confidence sources	4
Admitted final sources	13

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (contextual adjacent evidence, immune and inflammation, longevity, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. This run is certified under the researka_agent_certified accountability model — trust is machine-verifiable rather than dependent on author signoff.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=9; claims=236	no extracted directional signal in 9/9 sources	9 indirect	limited corpus depth in this outcome class
Immune and Inflammation	n=2; claims=128	no extracted directional signal in 2/2 sources	2 indirect	limited corpus depth in this outcome class
Longevity	n=1; claims=1	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Safety and Comorbidity	n=1; claims=27	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating

This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

Contextual Adjacent Evidence Outcomes

9 included sources were assigned to this outcome class. Directional coding: null=9. Directness coding: indirect=9.

Immune Inflammation Outcomes

2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: indirect=2.

Longevity Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Safety Comorbidity Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus is composed entirely of observational cohort designs, with no randomized controlled trials or quasi-experimental studies of oral microbiome interventions and aging-related outcomes represented. While mechanistic and associative signals are plentiful, the absence of interventional evidence means that causal claims about microbiome-directed therapies for periodontitis or age-related oral dysbiosis cannot be drawn from this body of work. Long-term mortality or hard cardiovascular endpoint trials involving the oral microbiome–periodontal disease axis were not identified in the corpus, creating a fundamental gap between microbiome signatures and clinically actionable endpoints. As such, conclusions about the therapeutic potential of modulating the oral microbiome for aging-related periodontitis remain provisional and hypothesis-generating only.

Several outcome domains within this synthesis rest on single-study evidence, precluding within-corpus replication or triangulation. For example, the association between oral microbiome composition and cognitive performance is supported solely by Adnan 2025, while the link between periodontal dysbiosis and non-alcoholic fatty liver disease rests exclusively on Kuraji 2024, an animal-model study using a nisin lantibiotic intervention in mice. Similarly, the koala-specific microbiome–periodontal disease data from Pettett 2025 represents a unique taxonomic context that cannot be cross-validated against any other source in the corpus. These single-trial touchpoints mean that effect sizes and directionality for these associations remain unconfirmed and may not generalize beyond their original study populations.

Population external validity is limited by the demographic profiles enrolled across the corpus. Several studies restricted enrollment to adults with existing periodontitis of varying severity (Plachokova 2021, Balan 2025, Yama 2023), while Stephen 2025 specifically examined children with primary immunodeficiency (n = 24) — a niche population whose microbiome–immune interactions may not extend to immunocompetent older adults. The cognition-focused analyses in Adnan 2025 targeted older adults, but Anderson 2023 studied cats with chronic gingivostomatitis, and Pettett 2025 characterized free-ranging koalas, introducing cross-species extrapolation challenges. Notably, no source in the corpus enrolled cohorts specifically selected for advanced age with longitudinal follow-up sufficient to capture aging trajectories in the oral microbiome, leaving the aging dimension of this synthesis largely inferential rather than empirically grounded.

The endpoint scope of the corpus is predominantly compositional and inflammatory rather than functional or clinically hard. Most studies reported microbial diversity metrics, taxonomic shifts, and salivary or serum cytokine levels (Gottschalk 2026, Plachokova 2021, Ishihara 2025), but none captured tooth loss, edentulism incidence, or validated periodontal treatment success rates as primary aging-relevant endpoints. Furthermore, the mechanism-to-clinic gap is pronounced: Viana 2025 provides a mechanistic narrative linking neutrophil lifespan and oral microbiome dysbiosis, yet no source in the corpus bridges this mechanistic pathway to a measured clinical outcome in older adults, leaving the translational logic from immune cell biology to periodontal aging outcomes empirically unsupported.

Conclusion

For oral microbiome periodontal aging, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

What This Synthesis Adds

This synthesis maps 13 included sources on Oral microbiome across 4 outcome classes and 37 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 13 curated reference papers, the evidence base for Oral microbiome shows a context-dependent profile. Null findings dominate: contextual other, immune inflammation. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Oral microbiome anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

The strongest unresolved contrast is the agreement between Yama 2023 and Kuraji 2024 on contextual adjacent evidence (severity 1/5), which defines the boundary condition future studies must test rather than smooth over.

This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
longevity	0	1	null	direct interventional hard-endpoint gap
contextual adjacent evidence	0	9	null	direct interventional hard-endpoint gap
immune and inflammation	0	2	null	direct interventional hard-endpoint gap
safety and comorbidity	0	1	null	direct interventional hard-endpoint gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	longevity: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null
P2	contextual adjacent evidence: direct interventional hard-endpoint gap	0 direct and 9 indirect sources; direction profile: null
P3	immune and inflammation: direct interventional hard-endpoint gap	0 direct and 2 indirect sources; direction profile: null
P4	safety and comorbidity: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null

Next-Study Design Recommendation

The next high-yield study for Oral microbiome should target the longevity evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

Additional corpus sources included animal/preclinical evidence; - Gottschalk 2026; tier=B2; directness=indirect; endpoint=immune inflammation; direction=null; representative statistic=P < 0.0001.

• Kuraji 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.001.
• Balan 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.05.
• Anderson 2023; tier=B2; directness=indirect; endpoint=safety comorbidity; direction=null; representative statistic=P < 0.01.
• Stephen 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.01.
• Baima 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.001.
• Ishihara 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.001.
• Plachokova 2021; tier=B2; directness=indirect; endpoint=immune inflammation; direction=null; representative statistic=P < 0.01.
• Pettett 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.03.
• Yama 2023; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.01.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• Potential biomarkers for early periodontal inflammation: investigating CD5 + B cells, salivary cytokines and oral microbiome: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=109.
• Nisin lantibiotic prevents NAFLD liver steatosis and mitochondrial oxidative stress following periodontal disease by abrogating oral, gut and liver dysbiosis: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=84.
• Oral Microbiome Signatures in Periodontitis and Edentulism—A Population‐Based Study: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=50.
• The Oral Microbiome across Oral Sites in Cats with Chronic Gingivostomatitis, Periodontal Disease, and Tooth Resorption Compared with Healthy Cats: outcome=safety comorbidity; directness=indirect; tier=B2; direction=null; claims=27.
• Non‐Surgical Periodontal Therapy Modulates Oral Microbiome in Primary Immunodeficient Children: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=21.
• Multi‐Omics Signatures of Periodontitis and Periodontal Therapy on the Oral and Gut Microbiome: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=20.
• Involvement of propionate, citrulline, homoserine, and succinate in oral microbiome metabolite-driven periodontal disease progression: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=19.
• Oral Microbiome in Relation to Periodontitis Severity and Systemic Inflammation: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=19.
• The Oral Microbiome in Queensland Free-Ranging Koalas ( Phascolarctos cinereus ) and Its Association with Age and Periodontal Disease: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=15.
• Dysbiosis of oral microbiome persists after dental treatment-induced remission of periodontal disease and dental caries: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=15.
• Oral microbiome brain axis and cognitive performance in older adults: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=7.
• Association between Periodontal Disease and Alzheimer's Disease Risk Factors: A Longitudinal Oral Microbiome Study: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=5.
• Neutrophils at the Crossroads of Oral Microbiome Dysbiosis and Periodontal Disease: outcome=longevity; directness=indirect; tier=B2; direction=null; claims=1.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Agreements

• Severity 1 agreement: Yama 2023 vs Kuraji 2024; Yama 2023 (null) vs Kuraji 2024 (null) on contextual other
• Severity 1 agreement: Yama 2023 vs Ishihara 2025; Yama 2023 (null) vs Ishihara 2025 (null) on contextual other
• Severity 1 agreement: Yama 2023 vs Pettett 2025; Yama 2023 (null) vs Pettett 2025 (null) on contextual other
• Severity 1 agreement: Yama 2023 vs Stephen 2025; Yama 2023 (null) vs Stephen 2025 (null) on contextual other
• Severity 1 agreement: Yama 2023 vs Yang 2025; Yama 2023 (null) vs Yang 2025 (null) on contextual other
• Severity 1 agreement: Yama 2023 vs Balan 2025; Yama 2023 (null) vs Balan 2025 (null) on contextual other
• Severity 1 agreement: Yama 2023 vs Baima 2025; Yama 2023 (null) vs Baima 2025 (null) on contextual other
• Severity 1 agreement: Yama 2023 vs Adnan 2025; Yama 2023 (null) vs Adnan 2025 (null) on contextual other

References

• Gottschalk 2026. Potential biomarkers for early periodontal inflammation: investigating CD5 + B cells, salivary cytokines and oral microbiome. Scientific Reports, 2026. DOI: 10.1038/s41598-026-37044-6. PMID: 41708693.
• Kuraji 2024. Nisin lantibiotic prevents NAFLD liver steatosis and mitochondrial oxidative stress following periodontal disease by abrogating oral, gut and liver dysbiosis. NPJ Biofilms and Microbiomes, 2024. DOI: 10.1038/s41522-024-00476-x. PMID: 38233485.
• Balan 2025. Oral Microbiome Signatures in Periodontitis and Edentulism—A Population‐Based Study. Journal of Periodontal Research, 2025. DOI: 10.1111/jre.70046. PMID: 41175138.
• Anderson 2023. The Oral Microbiome across Oral Sites in Cats with Chronic Gingivostomatitis, Periodontal Disease, and Tooth Resorption Compared with Healthy Cats. Animals : an Open Access Journal from MDPI, 2023. DOI: 10.3390/ani13223544. PMID: 38003162.
• Stephen 2025. Non‐Surgical Periodontal Therapy Modulates Oral Microbiome in Primary Immunodeficient Children. Journal of Clinical Periodontology, 2025. DOI: 10.1111/jcpe.14201. PMID: 40685148.
• Baima 2025. Multi‐Omics Signatures of Periodontitis and Periodontal Therapy on the Oral and Gut Microbiome. Journal of Periodontal Research, 2025. DOI: 10.1111/jre.70055. PMID: 41307322.
• Ishihara 2025. Involvement of propionate, citrulline, homoserine, and succinate in oral microbiome metabolite-driven periodontal disease progression. Scientific Reports, 2025. DOI: 10.1038/s41598-025-91105-w. PMID: 40021789.
• Plachokova 2021. Oral Microbiome in Relation to Periodontitis Severity and Systemic Inflammation. International Journal of Molecular Sciences, 2021. DOI: 10.3390/ijms22115876. PMID: 34070915.
• Yama 2023. Dysbiosis of oral microbiome persists after dental treatment-induced remission of periodontal disease and dental caries. mSystems, 2023. DOI: 10.1128/msystems.00683-23. PMID: 37698410.
• Pettett 2025. The Oral Microbiome in Queensland Free-Ranging Koalas ( Phascolarctos cinereus ) and Its Association with Age and Periodontal Disease. Animals : an Open Access Journal from MDPI, 2025. DOI: 10.3390/ani15131834. PMID: 40646733.
• Adnan 2025. Oral microbiome brain axis and cognitive performance in older adults. NPJ dementia, 2025. DOI: 10.1038/s44400-025-00004-4. PMID: 41859568.
• Yang 2025. Association between Periodontal Disease and Alzheimer's Disease Risk Factors: A Longitudinal Oral Microbiome Study. Alzheimer's & Dementia, 2025. DOI: 10.1002/alz70856_103436.
• Viana 2025. Neutrophils at the Crossroads of Oral Microbiome Dysbiosis and Periodontal Disease. Microorganisms, 2025. DOI: 10.3390/microorganisms13112573. PMID: 41304258.